Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
ESMO Open ; 6(1): 100010, 2021 02.
Article in English | MEDLINE | ID: mdl-33399076

ABSTRACT

BACKGROUND: The implementation of multidisciplinary tumor board (MDTB) meetings significantly ameliorated the management of oncological diseases. However, few evidences are currently present on their impact on pancreatic cancer (PC) management. The aim of this study was to evaluate the impact of the MDTB on PC diagnosis, resectability and tumor response to oncological treatment compared with indications before discussion. PATIENTS AND METHODS: All patients with a suspected or proven diagnosis of PC presented at the MDTB from 2017 to 2019 were included in the study. Changes of diagnosis, resectability and tumor response to oncological/radiation treatment between pre- and post-MDTB discussion were analyzed. RESULTS: A total of 438 cases were included in the study: 249 (56.8%) were presented as new diagnoses, 148 (33.8%) for resectability assessment and 41 (9.4%) for tumor response evaluation to oncological treatment. MDTB discussion led to a change in diagnosis in 54/249 cases (21.7%), with a consequent treatment strategy variation in 36 cases (14.5%). Change in resectability was documented in 44/148 cases (29.7%), with the highest discrepancy for borderline lesions. The treatment strategy was thus modified in 27 patients (18.2%). The MDTB brought a modification in the tumor response assessment in 6/41 cases (14.6%), with a consequent protocol modification in four (9.8%) cases. CONCLUSIONS: MDTB discussion significantly impacts on PC management, especially in high-volume centers, with consistent variations in terms of diagnosis, resectability and tumor response assessment compared with indications before discussion.


Subject(s)
Pancreatic Diseases , Pancreatic Neoplasms , Humans , Interdisciplinary Studies , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/therapy , Tertiary Care Centers
2.
Eur Rev Med Pharmacol Sci ; 23(19): 8625-8629, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31646596

ABSTRACT

OBJECTIVE: Cannabis is an illegal drug that has been under the spotlight in recent years, due to its vast array of effects on different biological systems. The role of cannabis has been investigated in the management of pain in acute pancreatitis (AP), even though some studies suggest that it may have a causative effect in this pathology and could be considered the underlying etiology in some cases of idiopathic AP. In this case report, we discuss the case of a young man who presented with three different episodes of AP, with apparently no significant history of alcohol and drug consumption, and with no evidence of a biliary, genetic or, autoimmune etiology. During the third episode, in which he had developed a voluminous pseudocyst, treated trough ultrasound (EUS)-guided drainage, he admitted consumption of cannabis daily. The Naranjo score resulted to be 6 (confirming the possible causality), and it was suggested to the patient to avoid cannabis consumption. Since then, he did not develop any other AP episodes. In summary, cannabis should be considered among the possible AP etiologies, as its causative identification and interruption may significantly improve the course of several idiopathic APs.


Subject(s)
Cannabinoids/adverse effects , Cannabis/adverse effects , Pancreatitis/chemically induced , Adult , Humans , Male , Pancreatitis/diagnostic imaging
3.
Eur Rev Med Pharmacol Sci ; 23(2): 771-787, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30720186

ABSTRACT

Acute pancreatitis (AP) is the most common gastrointestinal disorder requiring hospitalization, with a high rate of morbidity and mortality. Severe AP is characterized by the presence of persistent organ failure involving single or multiple organs. Clinical evolution, laboratory and radiological assessment are necessary to evaluate the prognosis and inform the management of AP. The onset of severe AP may be classified in two principal phases. The early phase, during the first week, is characterized by the activation of the auto-inflammatory cascade, gut dysbiosis, bacterial translocation, and the down-regulation of immune responses. The late phase is characterized by the development of local and systemic complications. Several old paradigms have been amended in the management of AP patients, such as the indication of nutrition, the use of antibiotic therapy, pain control strategies, and even the use of surgery. Real world evidence has shown that in the majority of cases a step-up approach is most effective. In this review, we discuss the clinical assessment and improvements to the management of patients with severe AP in a high volume center where a multi-disciplinary approach is performed.


Subject(s)
Multiple Organ Failure/therapy , Pain/drug therapy , Pancreatitis/therapy , Patient Care Team , Analgesics/therapeutic use , Anti-Bacterial Agents/therapeutic use , Bacterial Translocation/immunology , Cholangiopancreatography, Endoscopic Retrograde , Drainage/methods , Gastroenterostomy , Gastrointestinal Microbiome/immunology , Humans , Multiple Organ Failure/immunology , Nutrition Therapy/methods , Pain/immunology , Pain Management/methods , Pancreas/diagnostic imaging , Pancreas/immunology , Pancreas/pathology , Pancreas/surgery , Pancreatitis/complications , Pancreatitis/diagnosis , Pancreatitis/immunology , Severity of Illness Index , Tomography, X-Ray Computed
4.
Eur Rev Med Pharmacol Sci ; 21(22): 5179-5184, 2017 Nov.
Article in English | MEDLINE | ID: mdl-29228431

ABSTRACT

Pancreatic cystosis is a rare presentation of cystic fibrosis involving pancreatic gland. To date, only very few cases of pancreatic cystosis have been described in literature. Pancreatic cystosis may begin during the second decade of life and is the rarest presentation of cystic fibrosis. This disease is characterized by the presence of multiloculated cysts without ductal system communication of different sizes in all the pancreatic tissue. Herein, we report a case of a young woman affected by cystic fibrosis that was admitted to our Pancreatic Centre to evaluate a picture of diffuse multiloculated pancreatic cysts. After magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) assessment, we perform the diagnosis of the concomitant presence of the rare condition of pancreatic cystosis with Branch Duct-Intraductal Papillary Mucinous Neoplasm (BD-IPMN). To our knowledge, this is the first reported case of a cystic fibrosis patient with the combination of pancreatic cystosis and IPMN.


Subject(s)
Adenocarcinoma, Mucinous/complications , Cystic Fibrosis/complications , Pancreatic Cyst/complications , Papilloma, Intraductal/complications , Adenocarcinoma, Mucinous/diagnostic imaging , Cystic Fibrosis/diagnostic imaging , Endosonography , Female , Humans , Magnetic Resonance Imaging , Middle Aged , Pancreas/diagnostic imaging , Pancreatic Cyst/diagnostic imaging , Papilloma, Intraductal/diagnostic imaging
5.
Eur Rev Med Pharmacol Sci ; 21(12): 2858-2874, 2017 06.
Article in English | MEDLINE | ID: mdl-28682431

ABSTRACT

Intraductal Papillary Mucinous Neoplasms (IPMNs) are the most common cystic tumors of the pancreas and are considered premalignant lesions. IPMNs are characterized by the papillary growth of the ductal epithelium with rich mucin production, which is responsible for cystic segmental or diffuse dilatation of the main pancreatic duct (MPD) and/or its branches. According to the different involvement of pancreatic duct system, IPMNs are divided into main duct type (MD-IPMN), branch duct type (BD-IPMN), and mixed type (MT-IPMN). IPMNs may be incidentally discovered in asymptomatic patients, particularly in those with BD-IPMNs, when imaging studies are performed for unrelated indications. The increase in their frequency may reflect the combined effects of new diagnostic techniques, the improvement of radiologic exams and progress in the recognition of the pathology. MD-IPMNs present a higher risk of malignant progression than BD-IPMNs; as a consequence, all the guidelines strictly suggest the need of surgery for MD- and MT- IPMNs with MPD > 10 mm, while the management of BD-IPMNs is still controversial and depends on several cysts and patients features. The choice between non-operative and surgical management depends on the distinction between benign and invasive IPMN forms, assessment of malignancy risk, patient's wellness and its preferences. This manuscript revises the different guidelines for the management of IPMNs that have been published in different world countries: the international (Sendai 2006 and Fukuoka 2012), the 2013 European, the 2014 Italian, and finally the 2015 American guidelines. In summary, this review will integrate the recent insights in the combination of diagnostic techniques, such as Magnetic Resonance Imaging (MRI) and endoscopic ultrasound (EUS), pathology classification, and management of IPMNs.


Subject(s)
Adenocarcinoma, Mucinous/therapy , Adenocarcinoma, Papillary/therapy , Pancreatic Ducts/diagnostic imaging , Pancreatic Ducts/pathology , Pancreatic Neoplasms/therapy , Practice Guidelines as Topic , Adenocarcinoma, Mucinous/diagnostic imaging , Adenocarcinoma, Mucinous/pathology , Adenocarcinoma, Papillary/diagnostic imaging , Adenocarcinoma, Papillary/pathology , Endosonography , Humans , Magnetic Resonance Imaging , Pancreatic Neoplasms/diagnostic imaging , Pancreatic Neoplasms/pathology
7.
G Ital Med Lav Ergon ; 32(2): 154-61, 2010.
Article in Italian | MEDLINE | ID: mdl-20684436

ABSTRACT

There is no universally approved method in the scientific literature to identify subjects exposed to asbestos and divide them in classes according to intensity of exposure. The aim of our work is to study and develope an algorithm based on the findings of occupational anamnestical information provided by a large group of workers. The algorithm allows to discriminate, in a probabilistic way, the risk of exposure by the attribution of a code for each worker (ELSA Code--work estimated exposure to asbestos). The ELSA code has been obtained through a synthesis of information that the international scientific literature identifies as the most predictive for the onset of asbestos-related abnormalities. Four dimensions are analyzed and described: 1) present and/or past occupation; 2) type of materials and equipment used in performing working activity; 3) environment where these activities are carried out; 4) period of time when activities are performed. Although it is possible to have informations in a subjective manner, the decisional procedure is objective and is based on the systematic evaluation of asbestos exposure. From the combination of the four identified dimensions it is possible to have 108 ELSA codes divided in three typological profiles of estimated risk of exposure. The application of the algorithm offers some advantages compared to other methods used for identifying individuals exposed to asbestos: 1) it can be computed both in case of present and past exposure to asbestos; 2) the classification of workers exposed to asbestos using ELSA code is more detailed than the one we have obtained with Job Exposure Matrix (JEM) because the ELSA Code takes in account other indicators of risk besides those considered in the JEM. This algorithm was developed for a project sponsored by the Italian Armed Forces and is also adaptable to other work conditions for in which it could be necessary to assess risk for asbestos exposure.


Subject(s)
Asbestos/adverse effects , Asbestosis/epidemiology , Mesothelioma/epidemiology , Occupational Exposure/adverse effects , Pleural Neoplasms/epidemiology , Algorithms , Asbestosis/complications , Asbestosis/prevention & control , Humans , Italy/epidemiology , Mesothelioma/etiology , Mesothelioma/prevention & control , Meta-Analysis as Topic , Pleural Neoplasms/etiology , Pleural Neoplasms/prevention & control , Predictive Value of Tests , Risk Assessment , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL
...